Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients
Renate Kos(Amsterdam University Medical Centers), Anke H. Maitland‐van der Zee(Utrecht University), Ariana Lammers(Amsterdam University Medical Centers), Tamara Paff(Emma Kinderziekenhuis), Hettie M. Janssens(Erasmus MC), Paul Brinkman(Respiratory Clinical Trials), Christof J. Majoor(Amsterdam Neuroscience), Lieuwe D. J. Bos(Amsterdam Neuroscience), Aletta D. Kraneveld(Utrecht University), Harry Heijerman(University Medical Center Utrecht), Els J.M. Weersink(Amsterdam UMC Location University of Amsterdam), Jane C. Davies(Guy's and St Thomas' NHS Foundation Trust), Eric G. Haarman(Emma Kinderziekenhuis), Marije G. Gerritsen(Amsterdam University Medical Centers), Peter J. Sterk(Amsterdam UMC Location University of Amsterdam), Anne H. Neerincx(Amsterdam University Medical Centers)
Cited by 47
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855
What the pulmonary specialist should know about the new inhalation therapies
|European Respiratory Journal|2011|807
Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study
|The Lancet Respiratory Medicine|2017|645